Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTM6QSK)

• DTT Name: B-cell receptor CD22 (CD22) DTT Info
• Gene Name: CD22

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inotuzumab ozogamicin	DMAC130	Acute lymphoblastic leukaemia	2A85	Approved	[1]
Moxetumomab pasudotox	DMN63DZ	Hairy cell leukaemia	2A82.2	Approved	[2]
OspA lipoprotein	DMF5ZB3	Lyme disease	1C1G	Approved	[3]

34 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epratuzumab	DMI1ZXV	Acute lymphoblastic leukaemia	2A85	Phase 3	[4]
BL-22	DM8R71T	Acute lymphoblastic leukaemia	2A85	Phase 2	[5]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[6]
4SCAR19 and 4SCAR22	DM8CMUW	B-cell lymphoma	2A86	Phase 1/2	[7]
4SCAR19/22 T cells	DMI8TW3	B-cell lymphoma	2A86	Phase 1/2	[8]
Anti-CD19/22-CAR vector-transduced T cells	DMMUSHR	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[9]
Anti-CD22 CAR-T cells	DMY6U8R	leukaemia	2A60-2B33	Phase 1/2	[10]
Anti-CD22-CAR-transduced T cells	DMTO9VF	leukaemia	2A60-2B33	Phase 1/2	[11]
AUTO3	DMC5NSO	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[12]
CART-19/22	DMX0R1E	leukaemia	2A60-2B33	Phase 1/2	[13]
CD19 and CD22 CAR-T Cells	DM581CS	B-cell lymphoma	2A86	Phase 1/2	[14]
CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells	DM4MBUI	Haematopoietic/lymphoid cancer	2B33.5	Phase 1/2	[15]
CD22 CAR-T	DM40NEB	B-cell lymphoma	2A86	Phase 1/2	[16]
CD22-Targeted CAR-T cells	DM61MBG	leukaemia	2A60-2B33	Phase 1/2	[17]
Anti-CD22	DMUFRDK	Haematological malignancy	2B33.Y	Phase 1	[18]
CART-22 cells	DMLGJKE	Acute lymphoblastic leukaemia	2A85	Phase 1	[19]
CART22 cells	DM6X82R	Acute lymphoblastic leukaemia	2A85	Phase 1	[20]
CART22 cells expressing anti-CD22 scFv TCRz:41BB	DMY3NWK	Acute lymphoblastic leukaemia	2A85	Phase 1	[21]
CART22-65s cells	DM4XT15	Acute lymphoblastic leukaemia	2A85	Phase 1	[22]
CART22-65s cells and huCART19 Cells	DMOJ1AH	Acute lymphoblastic leukaemia	2A85	Phase 1	[22]
CD19/CD22 CAR T cells	DMVONF0	Acute lymphoblastic leukaemia	2A85	Phase 1	[23]
CD19/CD22 CAR T-Cells	DMKA2FL	Acute lymphocytic leukaemia	2B33.3	Phase 1	[24]
CD19/CD22 Chimeric Antigen Receptor T Cells	DMPADR1	Acute lymphoblastic leukaemia	2A85	Phase 1	[25]
CD22-CART	DMHMPK1	leukaemia	2A60-2B33	Phase 1	[26]
CD22-specific CAR T-cells also expressing an EGFRt	DMP5V83	leukaemia	2A60-2B33	Phase 1	[27]
Combotox	DMA7PWX	leukaemia	2A60-2B33	Phase 1	[28]
Donor-derived CD19/22 bispecific CAR-T cells	DMZS350	leukaemia	2A60-2B33	Phase 1	[29]
JCAR018	DMR3SO5	Acute lymphoblastic leukaemia	2A85	Phase 1	[30]
JNJ-75348780	DMSDSFX	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[31]
Lumoxiti	DMQI970	Hairy cell leukaemia	2A82.2	Phase 1	[32]
Patient-derived CD19- and CD22 specific CAR	DMZSD3T	leukaemia	2A60-2B33	Phase 1	[33]
Retroviral vector-transduced autologous T cells to express CD22-specific CARs	DMZ8WAQ	Diffuse large B-cell lymphoma	2A81	Phase 1	[34]
TRPH-222	DMSLQW2	B-cell lymphoma	2A86	Phase 1	[35]
UCART-22	DMARHU4	B-cell acute lymphoblastic leukaemia	2B33.3	Phase 1	[36]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DCDT-2980S	DMGM2HY	Diffuse large B-cell lymphoma	2A81	Discontinued in Phase 2	[37]
RG7593	DM32IV4	Haematological malignancy	2B33.Y	Discontinued in Phase 2	[38]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATA2431	DM34FEA	B-cell lymphoma	2A86	Preclinical	[39]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-CD22/CD19 mab-toxin conjugate	DM8QIB2	Acute lymphoblastic leukaemia	2A85	Investigative	[40]
MEDI-553	DM960DQ	Autoimmune diabetes	5A10	Investigative	[41]

References

• [1] Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
• [2] Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
• [3] Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
• [4] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [5] Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
• [6] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [7] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [8] ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
• [9] ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
• [10] ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [11] ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
• [12] ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
• [13] ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
• [14] ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
• [15] ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
• [16] ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies
• [17] ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
• [18] 2011 Pipeline of Seattle Genetics.
• [19] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [20] ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
• [21] ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL
• [22] ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
• [23] ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
• [24] ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
• [25] ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
• [26] ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
• [27] ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
• [28] A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6.
• [29] ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
• [30] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [31] ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health.
• [32] Clinical pipeline report, company report or official report of Innate Pharma.
• [33] ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
• [34] ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
• [35] Clinical pipeline report, company report or official report of Triphase Accelerator.
• [36] Clinical pipeline report, company report or official report of Cellectis.
• [37] Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 December 1; 1(9): 1469-1475.
• [38] Clinical pipeline report, company report or official report of Roche.
• [39] Clinical pipeline report, company report or official report of Atara Biotherapeutics.
• [40] Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2786).